Login to Your Account


Repatha: Clinical benefit yes, cost benefit no

By Anette Breindl
Senior Science Editor

Monday, March 20, 2017

Amgen Inc. presented detailed data for the FOURIER cardiovascular outcomes trial of its Repatha (evolocumab) at the American College of Cardiology (ACC) annual meeting, which showed that those benefits were clinically significant, not just statistically significant. But the magnitude of the effects reported also showed that for it to be cost-effective, Repatha's price will need to be significantly lower than its current list price of roughly $14,500 per year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription